NEW YORK (GenomeWeb News) – PerkinElmer reported after the close of the market on Thursday that its revenues for the second quarter increased 9 percent year over year, including 18 percent growth in its Human Health segment.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: factors influencing retrotransposon integration sites, and more.
A bioethicist argues for the responsible use of germline gene editing.
Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.
Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.